Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Akebia Therapeutics (AKBA) Misses Q1 EPS by 6c
May 9, 2022 4:22 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $61.7 million versus the consensus estimate of $44.22 million.
GUIDANCE:
Akebia Therapeutics sees FY2022 revenue of $165-170 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More